skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: TRAIL Death Receptor-4 Expression Positively Correlates With the Tumor Grade in Breast Cancer Patients With Invasive Ductal Carcinoma

Journal Article · · International Journal of Radiation Oncology, Biology and Physics
 [1];  [1]; ; ;  [2];  [3];  [4]
  1. Human Gene Therapy Unit, Akdeniz University Faculty of Medicine, Antalya (Turkey)
  2. Department of Pathology, Akdeniz University Faculty of Medicine, Antalya (Turkey)
  3. Department of Oncology, Akdeniz University Faculty of Medicine, Antalya (Turkey)
  4. Department of Urology, University of Iowa, Iowa City, IA (United States)

Purpose: Tumor necrosis factor-related apoptosis inducing ligand (TRAIL) selectively induces apoptosis in cancer cells but not in normal cells, and a number of clinical trials have recently been initiated to test the safety and antitumoral potential of TRAIL in cancer patients. Four different receptors have been identified to interact with TRAIL: two are death-inducing receptors (TRAIL-R1 [DR4] and TRAIL-R2 [DR5]), whereas the other two (TRAIL-R3 [DcR1] and TRAIL-R4 [DcR2]) do not induce death upon ligation and are believed to counteract TRAIL-induced cytotoxicity. Because high levels of DcR2 expression have recently been correlated with carcinogenesis in the prostate and lung, this study investigated the importance of TRAIL and TRAIL receptor expression in breast cancer patients with invasive ductal carcinoma, taking various prognostic markers into consideration. Methods and Materials: Immunohistochemical analyses were performed on 90 breast cancer patients with invasive ductal carcinoma using TRAIL and TRAIL receptor-specific antibodies. Age, menopausal status, tumor size, lymph node status, tumor grade, lymphovascular invasion, perineural invasion, extracapsular tumor extension, presence of an extensive intraductal component, multicentricity, estrogen and progesterone receptor status, and CerbB2 expression levels were analyzed with respect to TRAIL/TRAIL receptor expression patterns. Results: The highest TRAIL receptor expressed in patients with invasive ductal carcinoma was DR4. Although progesterone receptor-positive patients exhibited lower DR5 expression, CerbB2-positive tissues displayed higher levels of both DR5 and TRAIL expressions. Conclusions: DR4 expression positively correlates with the tumor grade in breast cancer patients with invasive ductal carcinoma.

OSTI ID:
21039573
Journal Information:
International Journal of Radiation Oncology, Biology and Physics, Vol. 69, Issue 3; Other Information: DOI: 10.1016/j.ijrobp.2007.03.057; PII: S0360-3016(07)00652-9; Copyright (c) 2007 Elsevier Science B.V., Amsterdam, Netherlands, All rights reserved; Country of input: International Atomic Energy Agency (IAEA); ISSN 0360-3016
Country of Publication:
United States
Language:
English

Similar Records

Improved Outcomes of Breast-Conserving Therapy for Patients With Ductal Carcinoma in Situ
Journal Article · Thu Mar 15 00:00:00 EDT 2012 · International Journal of Radiation Oncology, Biology and Physics · OSTI ID:21039573

The Prognostic Value of TRAIL and its Death Receptors in Cervical Cancer
Journal Article · Tue Sep 01 00:00:00 EDT 2009 · International Journal of Radiation Oncology, Biology and Physics · OSTI ID:21039573

Capsaicin sensitizes TRAIL-induced apoptosis through Sp1-mediated DR5 up-regulation: Involvement of Ca{sup 2+} influx
Journal Article · Wed Feb 15 00:00:00 EST 2012 · Toxicology and Applied Pharmacology · OSTI ID:21039573